ジョンソン・エンド・ジョンソン、Platinum Equityのライフスキャン買収提案受諾

AsiaNet 73879 （1007）

【ニューブランズウィック（米ニュージャージー州）2018年6月13日PR Newswire＝共同通信JBN】ジョンソン・エンド・ジョンソン（Johnson & Johnson、NYSE: JNJ）は13日、傘下のライフスキャン事業を約21億ドルで買収したいとのPlatinum Equityによる拘束力のある提案（2018年3月16日に発表済み）を受諾したと発表した。ライフスキャン（LifeScan,Inc.）は世界有数の血糖モニター企業で、ワンタッチ（R）ブランド製品のメーカー。

買収受諾は関連作業部会や労働組合との協議を経て決定した。買収手続きは規制当局の承認と通常の買収条件を満たした上で、2018年末までに完了する見通し。

ジョンソン・エンド・ジョンソンの企業ファミリーは、医療機器や医薬品、コンシューマー事業からの革新的製品とサービス、ソリューションによって、糖尿病に苦しむ人々に奉仕し続ける。これには、肥満症治療手術などの分野や、INVOKANA（R）（カナグリフロジン）、INVOKAMET（R）（カナグリフロジン/メトホルミンHCl）といった医薬品を通じた重要なリーダーシップとイノベーションが含まれる。

▽ライフスキャン（LifeScan,Inc.）について

ライフスキャンは血糖モニターの世界的リーダー企業。米国では血糖モニターシステムの大手メーカーで、そのワンタッチ（R）ブランド製品は、内分泌内科医と一般開業医によって他のブランド製品よりも多く勧められている（注1）。世界では2000万人以上の人々が糖尿病を管理する簡単なテストと正確な結果を得るために、ワンタッチ（R）ブランド製品を利用している。詳しい情報はwww.OneTouch.com を参照。

▽ジョンソン・エンド・ジョンソン（Johnson & Johnson）について

ジョンソン・エンド・ジョンソンは、健康が豊かな人生と地域社会の繁栄、発展の基盤であると信じる。だからこそ130年以上も同社は、すべての年代、あらゆる人生段階の人々の健康を支えようと務めてきた。今日、世界最大級で広範な拠点を有するヘルスケア企業としての強みを最大限に活かし、世界中の誰もが、どこにいても、心身の健康と健全な環境を享受することができるよう、私たちは適正な価格でヘルスケアにアクセスできる、より健全な社会の実現に向けて努力している。私たちの想いと科学、創意工夫を一つにして、人類のため健康の流れを根本から変えようとしている。

（注1） Global Brand Equity Insights Study, February 2015

ソース：Johnson & Johnson

▽メディア問い合わせ先

Natalia Salomao

+1 (732) 325-8306

Nsaloma7@its.jnj.com

Donna Lorenson

+1 (410) 258-8571

dlorens@its.jnj.com

▽投資家問い合わせ先

Lisa Romanko

+1 (732) 524-2034

Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.

PR73879

NEW BRUNSWICK, New Jersey, June 13, 2018 /PRNewswire=KYODO JBN/ --

Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding

offer from Platinum Equity, previously announced on March 16, 2018, to acquire

its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world

leader in blood glucose monitoring and maker of the OneTouch(R) brand of

products.

This acceptance was made after consultation with relevant works councils and

trade unions. The transaction is expected to close by the end of 2018, subject

to the satisfaction of regulatory clearances and other customary closing

conditions.

The Johnson & Johnson Family of Companies will continue to serve those impacted

by diabetes through innovative products, services and solutions from its

Medical Device, Pharmaceuticals and Consumer businesses. These include

important leadership and innovation in areas such as bariatric surgery and

through medicines such as INVOKANA(R) (canagliflozin) and INVOKAMET(R)

(canagliflozin/metformin HCl).

About LifeScan

LifeScan, Inc. is a world leader in blood glucose monitoring. In the U.S.,

LifeScan, Inc. is the leading maker of blood glucose monitoring systems and its

OneTouch(R) brand products are recommended by more endocrinologists and primary

care physicians than any other brand(1). Globally, more than 20 million people

depend on OneTouch(R) brand products for simple testing and accurate results to

help them manage their diabetes. For more information visit: www.OneTouch.com.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant

lives, thriving communities and forward progress. That's why for more than 130

years, we have aimed to keep people well at every age and every stage of life.

Today, as the world's largest and most broadly-based health care company, we

are committed to using our reach and size for good. We strive to improve access

and affordability, create healthier communities, and put a healthy mind, body

and environment within reach of everyone, everywhere. We are blending our

heart, science and ingenuity to profoundly change the trajectory of health for

humanity.

Note on Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the

Private Securities Litigation Reform Act of 1995 related to the divestiture of

the LifeScan business. The reader is cautioned not to rely on these

forward-looking statements. These statements are based on current expectations

of future events. If underlying assumptions prove inaccurate or known or

unknown risks or uncertainties materialize, actual results could vary

materially from the expectations and projections of Johnson & Johnson. Risks

and uncertainties include, but are not limited to: the possibility that the

transaction will not be completed, or if completed, not completed in the

expected timeframe, and the potential that the expected strategic benefits or

opportunities from any divestiture may not be realized, or may take longer to

realize than expected. A further list and descriptions of these risks,

uncertainties and other factors can be found in Johnson & Johnson's Annual

Report on Form 10-K for the fiscal year ended December 31, 2017, including in

the sections captioned "Cautionary Note Regarding Forward-Looking Statements"

and "Item 1A. Risk Factors," and in the company's subsequent Quarterly Reports

on Form 10-Q and other filings with the Securities and Exchange Commission.

Copies of these filings are available online at www.sec.gov, www.jnj.com or on

request from Johnson & Johnson. Any forward-looking statement made in this

release speaks only as of the date of this release. Johnson & Johnson does not

undertake to update any forward-looking statement as a result of new

information or future events or developments.

(1) Global Brand Equity Insights Study, February 2015

SOURCE: Johnson & Johnson

CONTACT: Media Contact: Natalia Salomao, +1 (732) 325-8306,

Nsaloma7@its.jnj.com; Donna Lorenson, +1 (410) 258-8571, dlorens@its.jnj.com;

Investor Contact: Lisa Romanko, +1 (732) 524-2034